“Sopharma” AD (the Company) notifies that for June 2022 the Company recorded an increase in sales of 83% compared to the same month of the previous year, incl. 39% increase in domestic sales and 109% increase in export sales.
For the six months since the beginning of the year the revenues from sales of products increase by 37%, incl. 35% increase of sales for the domestic market and 38% increase in export sales.
| Data | Tytuł | Kurs | Zmiana |
|---|
2024-04-01 | SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022 | 13,40 | 0,00 |
2024-03-20 | SPH Sales revenues for February 2024 | 14,40 | -3,13 |
2024-03-12 | SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212 | 14,00 | -1,43 |
2024-03-11 | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase | 13,80 | +1,45 |
2024-02-29 | SPH Consolidated financial report as of 31 December 2023 | 13,70 | -2,19 |
2024-02-27 | SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212 | 13,40 | +2,99 |
2024-02-22 | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants | 13,75 | -0,73 |
2024-02-22 | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition | 13,75 | -0,73 |
2024-02-20 | SPH NOTIFICATION OF INSIDERS’ TRANSACTIONS under art. 19 of Regulation 596/2014 for subscribin shares from a temporary issue/exercising warrants | 14,70 | -8,84 |
2024-02-20 | SPH Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 as of 20 February 2024 re exercising warrants | 14,70 | -8,84 |
